CA2440767C - Novel neurotrophic factors - Google Patents

Novel neurotrophic factors Download PDF

Info

Publication number
CA2440767C
CA2440767C CA2440767A CA2440767A CA2440767C CA 2440767 C CA2440767 C CA 2440767C CA 2440767 A CA2440767 A CA 2440767A CA 2440767 A CA2440767 A CA 2440767A CA 2440767 C CA2440767 C CA 2440767C
Authority
CA
Canada
Prior art keywords
seq
arg
neublastin
ala
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2440767A
Other languages
English (en)
French (fr)
Other versions
CA2440767A1 (en
Inventor
Dinah Wen Yee Sah
Teit E. Johansen
Anthony Rossomando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NsGene AS
Biogen MA Inc
Original Assignee
NsGene AS
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NsGene AS, Biogen Idec MA Inc filed Critical NsGene AS
Publication of CA2440767A1 publication Critical patent/CA2440767A1/en
Application granted granted Critical
Publication of CA2440767C publication Critical patent/CA2440767C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4756Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
CA2440767A 2001-03-12 2002-03-12 Novel neurotrophic factors Expired - Fee Related CA2440767C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/804,615 2001-03-12
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors
PCT/EP2002/002691 WO2002072826A2 (en) 2001-03-12 2002-03-12 Neurotrophic factors

Publications (2)

Publication Number Publication Date
CA2440767A1 CA2440767A1 (en) 2002-09-19
CA2440767C true CA2440767C (en) 2012-05-29

Family

ID=25189406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2440767A Expired - Fee Related CA2440767C (en) 2001-03-12 2002-03-12 Novel neurotrophic factors

Country Status (15)

Country Link
US (1) US20020055467A1 (enExample)
EP (2) EP1373503B1 (enExample)
JP (2) JP3738008B2 (enExample)
CN (1) CN1268744C (enExample)
AT (2) ATE378353T1 (enExample)
AU (1) AU2002240943B2 (enExample)
CA (1) CA2440767C (enExample)
CY (1) CY1111750T1 (enExample)
DE (1) DE60223511T2 (enExample)
DK (2) DK1930439T3 (enExample)
ES (2) ES2296899T3 (enExample)
NZ (1) NZ528790A (enExample)
PT (2) PT1373503E (enExample)
SI (2) SI1373503T1 (enExample)
WO (1) WO2002072826A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
KR100773776B1 (ko) * 1998-07-14 2007-11-12 얀센 파마슈티카 엔.브이. 신경친화성 성장 인자
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
US7112321B2 (en) * 2001-12-19 2006-09-26 Genzyme Corporation Adeno-associated virus-mediated delivery of GDNF to skeletal muscles
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Jx日鉱日石エネルギー株式会社 潤滑油組成物
BRPI0407170A (pt) * 2003-01-31 2006-02-21 Biogen Idec Inc conjugados de polìmero de neoblastina mutada
CA2864810A1 (en) * 2003-04-18 2004-11-04 Biogen Idec Ma, Inc. Polymer-conjugated glycosylated neublastin
US7601518B2 (en) * 2003-06-10 2009-10-13 Nsgene A/S Secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
GEP20115196B (en) * 2004-08-19 2011-04-11 Biogen Idec Inc Neublastin variants
WO2007042040A2 (en) * 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
AU2008247637B2 (en) 2007-05-01 2013-12-05 Biogen Ma Inc. Compositions and methods for increasing vascularization
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20100247437A1 (en) * 2007-10-01 2010-09-30 Vgx Pharmaceuticals, Llc Materials and methods for the delivery of biomolecules to cells of an organ
EP2621512B1 (en) * 2010-10-01 2016-04-06 NsGene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛
AU2022278242B2 (en) 2021-05-18 2024-11-14 Ltt Bio-Pharma Co., Ltd. Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
TR199802252T2 (xx) 1996-05-08 1999-02-22 Biogen, Inc N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL)
WO2000073348A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor

Also Published As

Publication number Publication date
JP3738008B2 (ja) 2006-01-25
AU2002240943A2 (en) 2002-09-24
ATE509103T1 (de) 2011-05-15
CN1509333A (zh) 2004-06-30
EP1930439B1 (en) 2011-05-11
NZ528790A (en) 2004-06-25
EP1930439A1 (en) 2008-06-11
US20020055467A1 (en) 2002-05-09
WO2002072826A2 (en) 2002-09-19
CA2440767A1 (en) 2002-09-19
DK1930439T3 (da) 2011-08-29
SI1930439T1 (sl) 2011-09-30
DK1373503T3 (da) 2008-03-25
JP2004531242A (ja) 2004-10-14
PT1930439E (pt) 2011-07-25
EP1373503B1 (en) 2007-11-14
PT1373503E (pt) 2008-02-26
CY1111750T1 (el) 2015-10-07
HK1120556A1 (en) 2009-04-03
WO2002072826A3 (en) 2003-04-10
ATE378353T1 (de) 2007-11-15
AU2002240943B2 (en) 2007-05-10
EP1373503A2 (en) 2004-01-02
DE60223511T2 (de) 2008-10-23
DE60223511D1 (de) 2007-12-27
CN1268744C (zh) 2006-08-09
SI1373503T1 (sl) 2008-04-30
ES2296899T3 (es) 2008-05-01
ES2366610T3 (es) 2011-10-21
JP2005198656A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
CA2336218C (en) Neurotrophic factors
US7655463B2 (en) Methods of activating RET receptor tyrosine kinase using neurotrophic factors
CA2440767C (en) Novel neurotrophic factors
AU2002240943A1 (en) Neurotrophic factors
IL140259A (en) Neublastin neurotrophic factors and use thereof for preparation of medicaments
ZA200007404B (en) Neurotrophic factors.
HK1120556B (en) Neurotrophic factors
HK1117870A (en) Neurotrophic factors
MXPA01000104A (en) Neurotrophic factors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170313